Certainly. Below is a **detailed, comprehensive summary** of the regulation you provided ‚Äî the *Patented Medicines Regulations*, as amended and ultimately **repealed** in 2008 ‚Äî with clear explanations of its purpose, structure, key provisions, and implications.

---

## üîç **Detailed Summary of the Patented Medicines Regulations (1993)**  
*(Repealed by SOR/2008-70, s. 2 and s. 4)*

> **Original Enactment**:  
> Made by Order in Council P.C. 1988-2013 (September 15, 1988),  
> Replaced and revoked by the Governor in Council on the recommendation of the Minister of National Health and Welfare, pursuant to **section 101 of the Patent Act**, under **S.C. 1993, c. 2, s. 7**.  
> **Final Status**: **Repealed** on **April 1, 2008**, under **SOR/2008-70, s. 2 and s. 4**.

---

### üéØ **Purpose of the Regulation**

The primary objective of these regulations was to **promote transparency** in the pharmaceutical industry by requiring **patent holders** and **licensees** to disclose specific information about:

1. **Patented medicines** (including details of patents, expiry dates, and supplementary protection certificates),
2. **Sales pricing and revenue** (including average prices, net revenue, and ex-factory prices),
3. **Research and development (R&D) expenditures**.

This transparency aimed to:
- Support **public access to drug pricing and innovation data**,
- Enable **informed policy decisions** regarding access to medicines,
- Encourage **innovation and fair competition** in the pharmaceutical market,
- Ensure that **public health and patient access** are not compromised by monopolistic pricing.

> ‚ö†Ô∏è **Note**: Although the regulation was intended to serve public interest, it was ultimately **repealed in 2008**, indicating that its implementation was either deemed ineffective, outdated, or superseded by newer regulatory frameworks (such as the *Pharmaceutical Pricing and Access Act* or updated provisions under the *Patent Act* and *Food and Drug Regulations*).

---

## üìö Key Definitions

| Term | Definition |
|------|-----------|
| **Act** | Refers to the *Patent Act* |
| **Notice of Compliance (NoC)** | A regulatory document issued under the *Food and Drug Regulations* confirming that a medicine has met safety and efficacy standards for sale in Canada. |
| **Rights Holder** | The person or entity holding rights to a patented medicine ‚Äî includes patent holders, certificate holders, or licensees (excluding those continuing under subsection 11(1) of the Patent Act Amendment Act, 1992). |

---

## üìù Core Provisions (by Section)

---

### ‚úÖ **Section 1: Information Required for Medicines (Paragraphs 80(1)(a) and (2)(a))**

**What must be disclosed?**  
When a medicine is being sold or a notice of compliance is issued, the rights holder must provide detailed information identifying the medicine and its patent status.

#### Required Information Includes:
1. **Name and address** of the rights holder (or former rights holder) and their Canadian correspondence address.
2. **Type of rights holder**:
   - Patent holder?
   - Holder of a **certificate of supplementary protection**?
   - Licensee (not continuing under 11(1) of the 1992 amendment)?
3. **Generic and brand name** of the medicine.
4. **Use of the medicine**:
   - Human or veterinary?
5. **Therapeutic use** approved by the Minister of Health.
6. **First date of notice of compliance** issued to the rights holder.
7. **Drug Identification Number (DIN)** assigned under the *Food and Drug Regulations* for each strength and dosage form.
8. **Patent details**:
   - Patent number
   - Grant date
   - Expiry date
9. **Supplementary Protection Certificates (SPCs)**:
   - Certificate number
   - Start and end dates
   - Patent number referenced in the SPC application

#### When Must This Information Be Provided?
- **Within 7 days** of:
  - First issuance of a Notice of Compliance (NoC), **or**
  - First offering of the medicine for sale in Canada.
- **Exception**: In specific cases, information must be submitted **within 30 days** after the **Board requests** it.

#### Specific Exceptions (Where 30-Day Deadline Applies):
1. The medicine is **not a prescription drug** and is **not listed in Schedule D** of the *Food and Drugs Act*.
2. The medicine contains a **controlled substance** whose sale does **not require a prescription**.
3. The NoC was issued based on a submission under **section C.08.002.1** of the *Food and Drug Regulations*.
4. The medicine is for **veterinary use**.

#### Updates to Information:
- Any **change** in information (e.g., new patent term, expiry date) must be reported **within 30 days** of the change.
- Specifically includes updates to **additional patent terms** granted via:
  - Certificate of Additional Term (CAT) under **subsection 117.04(3)** of the *Patent Rules*, or
  - Orders under **subsection 46.4(2)** of the *Patent Act*.

> üîç *Purpose*: Ensures that the public and regulators have accurate, up-to-date data on patent timelines and medicine availability.

---

### ‚úÖ **Section 2: Pricing and Sales Information (Paragraphs 80(1)(b) and (2)(b))**

**What must be disclosed?**  
Information on **sales pricing and revenue** for the medicine.

#### Required Elements:
1. Identity of rights holder or former holder.
2. Generic and brand name of the medicine.
3. Date of first sale in Canada.
4. Day or period (e.g., six-month period) to which the data applies.
5. **Drug Identification Number (DIN)** or alternative ID for each dosage form and strength.
6. For each **six-month period** (Jan 1, July 1):
   - **Quantity sold** in final dosage form.
   - **Average price per package** (after promotions, rebates, discounts, etc.).
   - **Net revenue** from sales (after deductions for rebates, discounts, taxes).
   - **Publicly available ex-factory price** (in local currency) for:
     - Each dosage form, strength, and package size
     - For each **class of customer** (e.g., hospitals, pharmacies, wholesalers)
     - In **each province and territory**
     - In **specified foreign countries** (as listed in a schedule)

#### Reporting Deadlines:
- **Within 30 days** after:
  - The day the medicine is first sold in Canada.
  - The end of each **six-month period** (January 1 and July 1).
- **Exception**: In the same cases as above (non-prescription, controlled substance, etc.), the information must be provided **within 30 days of a Board request**, and **during the two years following the request**, within 30 days of each six-month period end.

#### Key Calculations:
- **Average price per package** and **net revenue**:
  - Must exclude **promotions, rebates, free goods, gifts, refunds, or other benefits**.
  - Must **deduct federal sales tax**.
- **Ex-factory price**:
  - Must be **agreed upon** between the rights holder and the **regulatory authority** of the country where sold.
  - Must be expressed in the **local currency** of the country.

#### Exceptions:
- Does **not apply** to sales to:
  - A person with whom the rights holder is **not dealing at arm‚Äôs length**.
  - Another rights holder or former rights holder.
- If the medicine is resold to a non-arm‚Äôs-length party, the **original rights holder must provide pricing information** for that resale.

#### Arm‚Äôs Length Determination:
- Governed by the **Income Tax Act as of December 1, 1987**.
- The Board uses this to assess whether a transaction was fair and commercially reasonable.

> üîç *Purpose*: To promote **transparency in pricing**, especially for generic and patented drugs, and to allow comparison across provinces and countries.

---

### ‚úÖ **Section 3: R&D Expenditure and Licensee Information (Subsection 88(1))**

**What must be disclosed?**  
For each calendar year, information about the **rights holder‚Äôs R&D activities** and **licensees in Canada**.

#### Required Information:
1. Name and address of:
   - Rights holder
   - All licensees in Canada
2. **Total gross revenues** from sales in Canada (human and veterinary) by:
   - The rights holder
   - All licensees
3. **Summary of R&D expenditures**:
   - Type of research (e.g., clinical trials, formulation)
   - Name of entity or person conducting R&D
   - Amount spent per type of R&D
   - Province where R&D was conducted
   - Expenditures in that province

#### Reporting Deadline:
- **Within 60 days after the end of each calendar year**.

#### Definition of "